Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$734M |
| 2 |
Adobe
ADBE
|
+$488M |
| 3 |
Merck
MRK
|
+$443M |
| 4 |
Tesla
TSLA
|
+$366M |
| 5 |
AGN
Allergan plc
AGN
|
+$315M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$682M |
| 2 |
Perrigo
PRGO
|
+$585M |
| 3 |
Gilead Sciences
GILD
|
+$556M |
| 4 |
EMC
EMC CORPORATION
EMC
|
+$432M |
| 5 |
Morgan Stanley
MS
|
+$401M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.29% |
| 2 | Consumer Discretionary | 15.4% |
| 3 | Communication Services | 11.3% |
| 4 | Technology | 10.76% |
| 5 | Energy | 10.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OMN
676
DELISTED
OMNOVA Solutions Inc.
OMN
| $445K | ﹤0.01% |
48,847
-722,541
| -94% | -$6.2M |
|
677
Omnicell
OMCL
$1.51B
| $444K | ﹤0.01% |
17,389
-213
| -1% | -$5.09K |
|
678
Shutterstock
SSTK
$221M
| $433K | ﹤0.01% |
5,177
-69,823
| -93% | -$5.17M |
|
|
HBI
679
DELISTED
Hanesbrands
HBI
| $416K | ﹤0.01% |
23,708
-728
| -3% | -$12.1K |
|
680
Euronet Worldwide
EEFT
$2.62B
| $402K | ﹤0.01% |
+8,399
| New | +$377K |
|
681
Post Holdings
POST
$3.87B
| $397K | ﹤0.01% |
12,302
-15,656
| -56% | -$461K |
|
682
Hancock Whitney
HWC
$6.02B
| $385K | ﹤0.01% |
+10,494
| New | +$354K |
|
683
B&G Foods
BGS
$286M
| $383K | ﹤0.01% |
11,294
-17,699
| -61% | -$607K |
|
|
RDS.A
684
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
| $382K | ﹤0.01% |
5,731
-7,009
| -55% | -$440K |
|
685
Oxford Industries
OXM
$572M
| $373K | ﹤0.01% |
4,618
-142
| -3% | -$10.3K |
|
|
CVD
686
DELISTED
COVANCE INC.
CVD
| $371K | ﹤0.01% |
4,214
-3,791
| -47% | -$328K |
|
687
Insperity
NSP
$2.04B
| $361K | ﹤0.01% |
19,962
-610
| -3% | -$10.9K |
|
688
iShares Russell 1000 Growth ETF
IWF
$126B
| $360K | ﹤0.01% |
16,764
-112,568
| -87% | -$2.31M |
|
|
NUVA
689
DELISTED
NuVasive, Inc.
NUVA
| $358K | ﹤0.01% |
+11,071
| New | +$333K |
|
690
Lennar Class A
LEN
$20.8B
| $337K | ﹤0.01% |
8,960
-9,789
| -52% | -$330K |
|
691
Newmont
NEM
$135B
| $334K | ﹤0.01% |
14,519
-799,872
| -98% | -$20.5M |
|
|
ETP
692
DELISTED
Energy Transfer Partners L.p.
ETP
| $303K | ﹤0.01% |
+5,289
| New | +$281K |
|
|
WPZ
693
DELISTED
WILLIAMS PARTNERS L.P. COM UTS REPTG L.P. INT
WPZ
| $285K | ﹤0.01% |
+5,954
| New | +$286K |
|
|
OKS
694
DELISTED
Oneok Partners LP
OKS
| $274K | ﹤0.01% |
+5,211
| New | +$275K |
|
|
EEP
695
DELISTED
Enbridge Energy Partners
EEP
| $258K | ﹤0.01% |
+8,645
| New | +$258K |
|
696
Tenaris
TS
$27.2B
| $253K | ﹤0.01% |
5,784
-7,076
| -55% | -$321K |
|
|
NE
697
DELISTED
Noble Corporation
NE
| $241K | ﹤0.01% |
7,367
-9,015
| -55% | -$299K |
|
698
Enterprise Products Partners
EPD
$84.3B
| $215K | ﹤0.01% |
+6,482
| New | +$202K |
|
|
DCP
699
DELISTED
DCP Midstream, LP
DCP
| $212K | ﹤0.01% |
+4,220
| New | +$203K |
|
|
ENLK
700
DELISTED
EnLink Midstream Partners, LP
ENLK
| $212K | ﹤0.01% |
+7,680
| New | +$190K |
|
Similar funds
Jennison Associates's Q4 2013 Portfolio in Review
As of Q4 2013, Jennison Associates held 759 positions worth $102B, up 6.9% from $95.4B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Jennison Associates's Q4 2013 filing shows 79 new, 184 increased, 411 reduced and 54 closed positions. Its largest new stake was Allergan plc: 2,016,619 shares worth $339M. The largest sale was UnitedHealth, an estimated $682M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q4 2013 buy was Allergan plc: 2,016,619 shares worth $339M.
- Jennison Associates added most to Bristol-Myers Squibb in Q4 2013, an estimated $734M increase.
- Jennison Associates's biggest Q4 2013 reduction was UnitedHealth, cutting an estimated $682M.
- Jennison Associates fully exited Perrigo in Q4 2013, selling an estimated $585M.
- Jennison Associates's ten largest holdings make up 20% of its $102B portfolio in Q4 2013.
- Jennison Associates opened 79 new positions and closed 54 in Q4 2013.
- Jennison Associates's portfolio value rose 6.9% quarter-over-quarter to $102B.
Based on Jennison Associates's 13F filing for Q4 2013, filed 10 Feb 2014.